STAT

AUGUST 16, 2023

The Chinese companies hope to compete with the Danish pharma group Novo Nordisk’s pioneering drugs in China, which has the world’s largest overweight and diabetic population. If successful, they could also potentially offer a cheaper alternative in the West.

Research Laboratories 246

Research Laboratories Documentation Diabetes Pharmaceutical Companies 246

European Pharmaceutical Review

MAY 30, 2024

The treatment is expected to advance into a pivotal Phase IIb/III trial in diabetic macular edema in the second half of 2024. This is based on positive results from the Phase Ib/IIa AMARONE study in diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Research Laboratories 96

Research Laboratories Diabetes 96

Pharmaceutical Business Review

JULY 15, 2024

This asset has potential applications in diabetic macular oedema (DME) and neovascular age-related macular degeneration (NVAMD). The acquisition includes EyeBio’s lead asset Restoret (EYE-103), a tetravalent, tri-specific antibody that targets the Wingless-related integration site (Wnt) signalling pathway.

Research Laboratories 59

Research Laboratories Diabetes Labelling 59

pharmaphorum

AUGUST 5, 2020

Metabolic diseases is already a focus area for Merck & Co – it markets several diabetes drugs including Januvia (sitagliptin) and last year exercised an option to develop NGM313, an antibody developed by NGM that could be used in NASH and type 2 diabetes.

Diabetes 52

Diabetes Research Laboratories 52